7 Investor presentation First six months of 2021 Solid diabetes sales growth acros Operations Reported diabetes sales and growth per IO geography DKK billion 30 25 20 15 10 5 0 13% 46% 6% IO Insulin GLP-1 Growth at CER 11% 36% 2% EMEA Geographical area 13% 68% 10% China 19% 69% 10% RoW Note: The share of growth development in 2021 is impacted by COVID-19 stocking in 2020 and the price reductions on oral-anti dia Source: IQVIA MAT, May 2021 (Spot rate) IO: International operations; NN: Novo Nordisk; pp: Percentage points; EMEA: Europe, Middle East and Africa; China: Mainland Chin
Download PDF file